Japan’s overall drug spending in FY2023 was pushed up by the cost growth associated with antiviral agents including those for COVID-19 and influenza, the Ministry of Health, Labor and Welfare (MHLW) said on September 11. In FY2023, which ended this…
To read the full story
Related Article
- Japan Healthcare Spend Hit Record High of 47 Trillion Yen in FY2023
September 4, 2024
REGULATORY
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Japan Finalizes Medical Data Sharing Blueprint, Eyes 2027 Bill
October 13, 2026
- AlliedCel Takes Over Sakigake Designation for Junten Bio’s T-Cell Therapy
October 13, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





